MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA

NDA FilingMDMA-assisted therapyPositive

AI Analysis

Summary

Resilient Pharmaceuticals resubmitted its NDA for MDMA-assisted therapy for PTSD to the FDA following a Complete Response Letter from August 2024 that requested additional research on durability, safety, and bias minimization. The resubmission represents progress toward potential regulatory approval.

Outcome Details

NDA resubmitted following Complete Response Letter from August 9, 2024, which recommended additional research on durability of response, safety characterization, and bias minimization

Importance:7/10

Sentiment:

0.40

MDMAPTSDNDA resubmissionComplete Response LetterFDAResilient Pharmaceuticals

Related Companies

$DRTSW

Read the original article

Published by GlobeNewswire Clinical Studies on August 10, 2026 6:46 PM

Read Original